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Abstract
Background: The international spread of wild poliomyelitis outbreaks continues to threaten eradication of poliomyelitis
and in 2014 a public health emergency of international concern was declared. Here we describe a risk scoring system
that has been used to assess country-level risks of wild poliomyelitis outbreaks, to inform prioritisation of mass
vaccination planning, and describe the change in risk from 2014 to 2016. The methods were also used to assess the risk
of emergence of vaccine-derived poliomyelitis outbreaks.
Methods: Potential explanatory variables were tested against the reported outbreaks of wild poliomyelitis since 2003
using multivariable regression analysis. The regression analysis was translated to a risk score and used to classify
countries as Low, Medium, Medium High and High risk, based on the predictive ability of the score.
Results: Indicators of population immunity, population displacement and diarrhoeal disease were associated
with an increased risk of both wild and vaccine-derived outbreaks. High migration from countries with wild
cases was associated with wild outbreaks. High birth numbers were associated with an increased risk of
vaccine-derived outbreaks.
Conclusions: Use of the scoring system is a transparent and rapid approach to assess country risk of wild
and vaccine-derived poliomyelitis outbreaks. Since 2008 there has been a steep reduction in the number of
wild poliomyelitis outbreaks and the reduction in countries classified as High and Medium High risk has
reflected this. The risk of vaccine-derived poliomyelitis outbreaks has varied geographically. These findings
highlight that many countries remain susceptible to poliomyelitis outbreaks and maintenance or improvement
in routine immunisation is vital.
Keywords: Poliomyelitis, Risk assessment, Regression, Outbreak, Vaccine-derived, Routine immunisation,
Vaccination, Migration
Background
Since the commitment to eradicate poliomyelitis in 1988
there has been a substantial reduction in the number of
cases of poliomyelitis, and poliovirus has been eliminated
from a majority of countries. India had successfully
eliminated wild poliomyelitis in 2014 [1], resulting in
considerable reduction in risk within the local population
and neighbouring countries. Following an absence of cases
for over 2 years, wild poliomyelitis was detected in Borno
State, Nigeria, in August 2016, where genetic sequencing
of the virus suggests undetected transmission since at least
2013. Endemic transmission continues in Pakistan and
Afghanistan, but here the incidence of wild poliomyelitis
cases has reached an all-time low [1].
Successful elimination of wild poliomyelitis from
India and substantial reduction in incidence in
Nigeria was the result of considerable efforts to im-
munise large numbers of children each year, primarily
through use of supplementary immunisation activities
* Correspondence: k.oreilly@imperial.ac.uk
1MRC Centre for Outbreak Analysis and Modelling, Department of Infectious
Disease Epidemiology, St Mary’s Campus, Imperial College London, London,
UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
O’Reilly et al. BMC Infectious Diseases  (2017) 17:367 
DOI 10.1186/s12879-017-2443-4
(SIAs). Transmission of poliomyelitis in Nigeria and
India prior to this time resulted in several outbreaks
of poliomyelitis in countries previously free from
disease. The large number of outbreaks, resulting in
the re-establishment of transmission in several coun-
tries, was a cause of great concern [2]. Since this time
there has been a refocus in resources and planning of
preventive SIAs, and development of country-specific
response plans [3].
A previous analysis of wild poliomyelitis outbreaks had
identified that population immunity, recent outbreaks,
extent of travel from infected countries and factors such
as the percentage of the population aged less than
15 years were associated with poliomyelitis outbreaks
[4]. This analysis set out a framework where preventive
SIAs could be planned based on inference from a statis-
tical model that captured the different contributions of
population immunity, migration from affected countries
and additional factors, rather than relying solely on ex-
pert assessment of risk. To this end, a multi-agency team
representing partners of the Global Polio Eradication
Initiative was established in 2014 to support SIA plan-
ning by providing an assessment of wild poliomyelitis
risk [5]. In addition to this international assessment of
risk, WHO regional offices make sub-national assess-
ments of poliomyelitis risk [6].
An inevitable consequence associated with the use of
the live attenuated oral polio vaccine (OPV) is the emer-
gence of vaccine-derived polioviruses (VDPVs), which in
some situations has led to outbreaks of poliomyelitis [7].
The first outbreak of VDPV was reported in Hispaniola
in 2000. Several studies have explored the mechanisms
leading to VDPV emergence; the attenuated poliovirus
strains used to produce the OPV naturally mutate and
these revertants with increased neurovirulence are
naturally selected during replication in the gut of OPV
recipients (sometimes resulting in cases of vaccine-
associated paralytic poliomyelitis [8]). Should this occur
in areas of low population immunity the revertants may
spread within populations, resulting in cases of paralytic
poliomyelitis where the isolated virus may have >1%
nucleotide sequence divergence (0.6% for serotype 2)
from the original Sabin strain, indicating ongoing circu-
lation [7]. Within Nigeria, districts with low routine im-
munisation coverage and a high number of births were
associated with a high probability of VDPV emergence
and circulation [9]. To eliminate the risks posed by
circulating VDPVs (cVDPVs) of serotype 2, OPV of this
serotype has been withdrawn from immunisation activ-
ities through a globally synchronised replacement of all
trivalent OPV with bivalent OPV and inclusion of at
least one dose of the inactivated poliovirus vaccine in
the routine immunisation schedule [10]. In the long-
term, withdrawal of serotype 2 from the OPV will
probably reduce the overall risks of cVDPV2s, but out-
breaks from serotypes 1 and 3 may still occur. To minimise
the risks associated with VDPVs while OPV is still in use, it
is important to understand the geographical variation in
risk and identify suitable measures to limit emergence.
A challenge associated with modelling of infectious
diseases is integration of research findings into public
health policy [11]. A mutually-beneficial, often long-
standing relationship between policy makers and epi-
demiological modellers is necessary for modelling infer-
ence to be successfully translated into policy, where the
timeliness and interpretability of modelling results are
critical to be useful. Here we describe a risk scoring
method that has been used to inform an international
poliomyelitis risk assessment since 2014 and can be rap-
idly applied to additional countries or additional time-
frames. The methodology is also applied to cVDPV risk
and the spatial and temporal variation in risk associated
with wild and cVDPV outbreaks are compared.
Methods
Description of the data
Outbreaks of poliomyelitis were identified through
global surveillance of acute flaccid paralysis (AFP) and
testing of stool specimens at WHO-accredited laborator-
ies of the Global Polio Laboratory Network [1]. The ini-
tial clinical symptoms of poliomyelitis are characterised
by the rapid onset of weakness, typically but not
exclusively in the lower limbs, with involuntary muscle
paralysis but no loss of sensation [12]. Isolation of the
virus from stool confirms poliomyelitis as opposed to
other (infectious and non-infectious) causes. Stool sam-
ples from all suspect cases and/or contacts are screened
for the presence of poliovirus, where real-time polymer-
ase chain reaction assays and sequence analysis are used
to determine the serotype and whether the isolated virus
is of wild or vaccine-derived origin [13, 14]. If multiple
poliomyelitis cases of the same genotype were identified
within a country, cluster analysis was used to determine
whether cases were a result of independent emergences or
transmission. For VDPVs an isolate was designated as
cVDPV if more than 1% (0.6% for serotype 2) nucleotide
divergence was apparent and there was evidence of trans-
mission (more than one related poliomyelitis case),
consistent with definitions developed by the Centers for
Disease Control [13]. The definition of a cVDPV has
changed since July 2015 to include more sensitive condi-
tions for detecting circulation [15], but for consistency
here we use the old definition. The number, timing and
country of origin of cVDPV outbreaks were compiled
from Centers for Disease Control reports from 2003 to
2016 (Additional file 1), where country outbreaks from
cross-border transmission (and identified through se-
quence analysis) were excluded. In some instances,
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cVDPV outbreaks may have been a result of one or more
emergent events and the six-month time period was classi-
fied as an emergent event occurring rather than the exact
number of events. The analysis was restricted to countries
within the AFRO, EMRO and SEARO regions and selected
countries in the EURO region (Kazakhstan, Kyrgyzstan,
Tajikistan, Turkey, Turkmenistan, Uzbekistan, Ukraine).
Surveillance for poliomyelitis captures all reported
cases of AFP where case investigation includes parental
recall of the number of OPV doses from routine immun-
isation and SIAs. The dose histories of non-polio AFP
cases from children aged 6–59 months recorded from 1
January 2003 to 28 July 2016 were used to estimate the
percentage of children under 5 years who were under-
immunised (received less than 3 OPV doses) and the
percentage of children who report zero OPV doses. Stat-
istical models were employed to provide country-level,
temporally-smoothed estimates in bins of six months for
the percentages of under-immunised and zero-dose
children. The models used first order-random walks to
model the temporal changes in the percentages along
with country level random intercepts to model overall
differences between countries [16]. The smoothed data
were especially relevant for small countries with limited
numbers of non-polio AFP cases. These estimates of
immunisation performance were used as indicators of
population immunity instead of estimating the percent-
age of the population protected from paralysis [17], as
the vaccine efficacy of the OPV is known to vary
between settings and estimates are only available from a
limited number of countries.
Indicators of OPV immunisation via routine services
were included in the analysis by using national estimates
of the third dose of the diphtheria-tetanus-pertussis
DTP3 vaccine, which is representative of three doses of
the OPV [18]. Other potential risk factors were hypothe-
sised based on expert opinion and previously published
research [6] (Table 1). Exposure to poliovirus associated
with population movement from countries with circula-
tion of wild poliovirus is well-known to be a risk factor
for international spread [4, 19], and several measures of
population movement were tested in the regression
analysis. Exposure to poliovirus experienced by coun-
try j per six-month time-period (λjt) was estimated
from data of economic migration [20] and refugees
[21] and poliomyelitis cases in country i in the previ-
ous six months (xi, t − 1) using λjt ¼ log
Pn
i¼1mijxi;t−1 ,
where t is the binned time period, m is the measure-
ment of migration and n is the total number of coun-
tries included in the analysis, as in [4].
International population movements rapidly change
according to economic drivers, political instability,
natural disasters and on occasion infectious diseases
(such as Ebola), where especially in low-income settings
the scale of movement is inconsistently documented or
is unrecorded. To account for population movements in
addition to that recorded (for example those reported by
epidemiological field investigators), expert opinion was
also incorporated into the risk assessment. The move-
ment patterns were assessed using a “likelihood-versus-
consequence” matrix [22], which is commonly used in
qualitative risk assessments (see Additional file 1). Infor-
mation on population movements from each country
were ranked according to the perceived likelihood of the
movements increasing the risk of virus transmission
across borders and the impact of such increased trans-
mission within the country of destination. Movements
assessed as high risk were allocated a score of 1 in the
risk assessment.
Statistical analysis
A mixed-effects logistic regression model was used to
identify factors associated with one or more wild polio-
myelitis outbreaks reported by a country or region for
every six months of the study period (1 January 2003 to
30 June 2016). The regression model consists of an
intercept (β0), fixed (β) and random variables (bi), ie.
logit(E(Yi ,t+ 1| β0, β, bi)) = β0 + Xi , tβ + bi. Explanatory vari-
ables significant (p < 0.2) in the univariable analysis were
tested in the multivariable model. In the multivariable
model variables were selected if a chi-squared test illus-
trated a significant (p < 0.05) association between the
variable and the outcome, and if the Akaike’s informa-
tion criteria reduced in value when compared to the re-
duced model. Interactions between model variables were
tested, and in some cases, risk factors were still included
in the final model even if the p-values were greater than
0.05. Regression analysis was also carried out to test for
associations with the emergence of cVDPVs of all sero-
types, again using a mixed-effects logistic regression
model. As cVDPV emergence is a function of exposure
to OPV which is largely driven by births and associated
routine immunisation activities [9], the annual number
of births for each country was forced into the model.
For the regression analysis birth numbers were in-
cluded on a natural log scale (which is analogous to
an offset term), and grouped into three categories;
<500,000, ≥500,000 to <1,000,000 and ≥1,000,000.
The coefficients of the final multivariable model were
used to develop a risk score. The score was calculated by
scaling the coefficients by the smallest coefficient of the
final risk model and rounding to the nearest integer
[23]. Variables on a continuous scale were grouped into
categories and the regression coefficient for the categor-
ical variables were used to calculate the risk score.
Country-level random effects were excluded. For com-
pilation with the other agency risk models, the risk score
was converted to four categories: Low, Medium,
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Medium High and High. The translation of the risk
score to the categories was made by balancing the sensi-
tivity, specificity and probability of experiencing an
outbreak.
The regression analysis of the probability of reporting
a poliomyelitis outbreak included only variables from the
previous time periods, enabling six-month ahead fore-
casts of the probability of reporting an outbreak in a
country. The predictions of each model were compared
to the outbreaks reported in the subsequent time-period.
Previous analysis had used “area under the curve”
diagnostics [4], but recent research has cautioned
against use of this assessment tool, opting instead for
the “H-measure” [24]. Here we display the analysis
using confusion matrices, and provide assessments of
model accuracy using the area under the curve and
H-measure. Higher H-measure values are associated
with more accurate and precise predictive measures.
The risk scoring was first applied to wild poliomyelitis
outbreaks in August 2014, and the analyses have been
repeated every six months since. Countries with endemic
circulation of wild poliovirus were excluded from the
risk assessment as SIAs within these countries were
determined independently, and details of a risk-based
analysis are found elsewhere [25, 26]. For consistency
with other assessments within the Global Polio
Table 1 Variables tested in the regressions models that were tested for an association with wild and VDPV outbreaks
Variable Description Data source Continuous/
discrete
Wild
outbreaks
cVDPV
outbreaks
Population immunity
Under-immunised Smoothed % of children under 5 yo with >2
OPV doses
AFP Both Y Y
Zero-dose Smoothed % children under 5 yo with 0
OPV doses
AFP Both Y Y
Routine immunisation % under 1 yo that received 3+ doses of the
DTP vaccine
WHO/Unicef Both Y Y
Surveillance quality
Stool surveillance % AFP cases under 15 yo with adequatea
stool samples processed
AFP Discrete Y Y
npAFP rate Number of non-polio AFP cases per 100,000
population under 15 yo
AFP Discrete Y Y
Historical propensity
Wild-type outbreaks Number of wild-type outbreaks reported in
last 4 years
WHO Both Y Not tested
Wild-type multi-case outbreaks Number of wild-type outbreaks with >1 case
reported in last 4 years
WHO Both Y Not tested
cVDPV outbreaks Number of VDPV outbreaks reported in last
4 years
Not tested Y
cVDPVs multi-case outbreaks Number of VDPV outbreaks with >1 case
reported in last 4 years
Not tested Y
Migration
Proximity Wild-type outbreak present in a bordering
country in last 6 months
Cluster
description
Discrete Y Not tested
Proximity scaled The number of poliomyelitis cases in
bordering countries in previous six months
Cluster
description
Continuous Y Not tested
Migrants Number of migrants multiplied by incidence
within country in previous 6 months
www.migrationdrc.org Both Y Not tested
Refugees Number of refugees multiplied by incidence
within country in previous 6 months
UNHCR Both Y Not tested
Humanitarian concern
Displaced % total population registered as refugees
and internally displaced persons
UNHCR Discrete Y Y
Other events (Ebola) Adverse humanitarian events that have
occurred in the previous 4 years
Expert opinion Discrete Y Y
aAdequate stools refer to two samples from AFP cases being collected ≥24 h apart, both within 14 days of paralysis onset
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Eradication Initiative (GPEI), countries reporting one or
more wild or vaccine-derived poliomyelitis cases were
allocated a High classification in the final risk score, and
countries identified as “vulnerable” by the Committee of
the Public Health Emergency of International Concern
[27] were allocated a Medium High risk. The risk
scoring method was first applied to cVDPV data in
August 2015, and included countries with endemic
poliomyelitis. The VDPV risk for July–December 2016
was not considered as the removal of serotype 2 from
the OPV formulation in April 2016 will affect the ex-
pected risk and accounting for this is beyond the scope
of the analysis.
All analyses were carried using R statistical program-
ming (v 3.3.1.).
Results
Wild poliomyelitis outbreaks
From January 2003 to 30 June 2016, 196 genetically
distinct wild outbreaks were reported within the AFRO,
EMRO, SEARO regions and selected EURO countries
(totalling 92 countries, Fig. 1). There were 150 (76.5% of
total) outbreaks of serotype 1, and the remainder were
serotype 3; 91 (46.4%) outbreaks consisted of multiple
cases and 13 outbreaks continued in excess of 1 year
within each country. The number of outbreaks reported
per six-month period varied from 0 to 21, with an aver-
age of 7.26 outbreaks per six-month period. The timing
of outbreaks peaked in the second half of both 2004 and
2008, which at the time corresponded to the peak in
incidence of poliomyelitis cases in Nigeria and other
countries in Central Africa. No cases were reported in
Nigeria since July 2014, until in August 2016 two polio-
myelitis cases were reported in Borno State with onset
of symptoms in July. These cases were genetically linked
to endemic transmission within Nigeria where the last
associated case was reported in 2013, meaning that
transmission has continued undetected since this time.
After 2007 there has been a gradual reduction in out-
breaks where the last wild outbreak was reported in Iraq,
consisting of two cases where the date of onset of the
first case was in February 2014. The last case of wild
poliomyelitis outside of the endemic countries was in
Somalia in August 2014.
In the multivariate model, factors significantly
(p < 0.05) associated with an increased probability of a
country reporting an outbreak were national DTP3 im-
munisation estimates below 80%, bordering countries
with poliomyelitis cases in the previous 6 months, a high
migration rate from countries reporting poliomyelitis
cases in the previous 6 months, diarrhoea-associated
mortality above 200 cases per 100,000 and experiencing
an outbreak in the previous 4 years (Table 2). Additional
indicators of population immunity (the percentage of
under-immunised and zero-dose non-polio AFP cases
above 20%) were also included in the final model even
though routine immunisation had the strongest associ-
ation with wild outbreaks out of the three population
immunity measures tested. The national estimate for
routine immunisation was updated annually whereas the
non-polio AFP measure was estimated every six months
and may consequently be more responsive to changes in
population immunity. Population displacement was also
included in the final risk model although its association
with wild poliomyelitis risk was non-significant
(p = 0.116). The data source for measuring population
displacement was updated every six months and may be
more responsive to changes in susceptibility, whereas
other data sources of migration and susceptibility do not
vary in time. Additionally, we identified that the inci-
dence of diarrhoea-associated mortality was confounded
with population displacement, and therefore both factors
were included in the risk model. Measures of migration
that may increase poliovirus exposure and countries
with humanitarian emergencies, both which were based
on expert opinion, were also included in the final risk
model.
The coefficients of the variables from the regression
model were converted into risk scores for each variable,
varying from 0 to 1 (Table 2). The risk score for an
individual country varied from 0 to 9, which was then
translated to a final classification with associated historic
probability of experiencing an outbreak (Table 4): Low;
0.8% (95% CI 0.4–1.3), Medium; 5.6% (95% CI 3.1–8.2),
Medium High; 18.5% (95% CI 14.3–23.9) and High;
35.2% (95% CI 24.2–46.4). If a High classification was
used as a cut-off to identify at-risk countries the model
had a sensitivity of 24.2%, but if Medium High and High
classifications were used the sensitivity improved to
69.7%, with a reduction in specificity to 86.5%.
The risk score has been used to classify countries in
six-month ahead forecasts from July–December 2014
onwards, where the model and variables used to assess
the risk have been slightly modified since this time. The
predictive ability of the forecasts from the regression
model, risk score and classification were assessed using
the H-measure; the regression model had a value of 0.453
and the risk score and classification models had values of
0.437 and 0.435 respectively (a ~ 3% reduction). Inclusion
of population immunity indicators (under-immunised and
zero-dose estimates) was associated with a small (<0.7%)
reduction in predictive ability and was not considered to
negatively influence the risk score. In the five rounds of
risk assessment the number of countries classified as Low
has increased from 39.0% to 77.5%, and the number of
countries classified as either Medium High or High
has decreased from 31.7% to 9.0% (Fig. 2). Within
this time-period, two outbreaks were reported in Iraq
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and Equatorial Guinea, where in the January–June
2014 risk assessment both countries were classified as
High. The detection of wild poliomyelitis in August
2016 in Nigeria resulted in increasing the outbreak
risk in neighbouring countries. Maps of the risk classi-
fication up to July–December 2016 are shown in Fig. 2;
Syria, South Sudan, South Africa, Indonesia and Mali were
classified as Medium risk and Yemen, Somalia, Niger,
Liberia, Chad, Central African Republic, Cameroon and
Equatorial Guinea were classified as Medium High.
Vaccine-derived poliomyelitis outbreaks
Based on the definition of cVDPVs used in this paper,
since 2003 there have been 35 outbreaks of cVDPVs,
located in 16 countries (Fig. 3). Nigeria and the Demo-
cratic Republic of the Congo (DRC) experienced over
ten outbreaks across the time period. A majority (n = 28
(80%)) of cVDPV outbreaks were of serotype 2; 5 out-
breaks (Indonesia 2005, Myanmar 2006, Mozambique
2011, Madagascar 2014 and Ukraine 2015) were of sero-
type 1 and 3 outbreaks (Yemen 2011 and 2012, Ethiopia
Fig. 1 Location (a) and timing (b) of wild poliomyelitis outbreaks within AFRO, EMRO, SEARO and selected EURO countries, 2003–2015. The publication
of this map does not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any territory, city, or area or of
its authorities, or concerning the delimitation of its frontiers or boundaries
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2009) were of serotype 3. Outbreaks within the Western
Pacific Region (reported in China and Lao People’s
Democratic Republic) were excluded from this analysis.
In the multivariable model four risk factors were associ-
ated with an increased probability of cVDPV outbreaks:
the national percentage of children under 2 immunised
with DTP3, reporting of cVDPV outbreaks in the previous
four years, the percentage of the population displaced and
the numbers of children born per year (Table 3). Estimates
of the percentage of children under-immunised and
reporting zero OPV doses were also included even though
their association with cVDPV outbreaks were non-
significant (p > 0.05). The regression coefficients were
used to calculate a risk score, which per variable varied
from 0 to 4, resulting in the risk score varying from 0 to 9.
The scores were converted into classifications and the
Fig. 2 Assessed risk of wild (a, c, e, g) and vaccine-derived (b, d, f) outbreaks of poliomyelitis from January–June 2015 to July–December 2016.
Confirmed outbreaks of wild and cVDPV within each time-period are also indicated and the parentheses indicate if outbreaks from previous
time-periods are on-going. Nigeria was included in the wild risk assessment in January–June 2016 and was re-classified as endemic when the
July–December 2016 risk assessment was made. The publication of this map does not imply the expression of any opinion whatsoever on the
part of WHO concerning the legal status of any territory, city, or area or of its authorities, or concerning the delimitation of its frontiers
or boundaries
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probability of experiencing an outbreak, sensitivity and
specificity are reported (Table 4). If Medium High and
High observations were used to identify countries at-risk
of a cVDPV outbreak, this was associated with a sensitivity
of 67.6% and specificity of 93.4%, where the sensitivity is
slightly lower in comparison to the wild risk assessment.
The predictive ability of the regression model, risk score
and classification were assessed using the H-measure, the
value for the regression model was 0.50 and the risk classi-
fication was 0.46 (an 8% reduction).
Between January–June 2015 to January–June 2016 the
Medium High and High VDPV risk were focussed within
populous countries and those with low routine immun-
isation, such as DRC, Ethiopia, Nigeria and Pakistan
(Fig. 2), and smaller countries such as Angola, Iraq,
Uganda, Yemen and Afghanistan. For the 2016 risk as-
sessment Pakistan, DRC, Ethiopia and Nigeria were
allocated a High or Medium High score. Outbreaks have
occurred in Guinea, Madagascar, South Sudan and
Ukraine when the country was classified as Low in the
Table 2 Explanatory variables used in the risk score to assess poliomyelitis outbreak risk, based on a regression analysis of data from
2003 to 2016
Variable Factor p-value Risk estimate (95% CI) Risk score
Population immunity
Under-immunised 0–20% of non-polio AFP
reporting 0–2 OPV doses
baseline 0
>20% of non-polio AFP
reporting 0–2 OPV doses
0.180 1.48 (0.84, 2.61) 1
Zero dose 0–20% of non-polio AFP
reporting 0 OPV doses
baseline 0
>20% of non-polio AFP
reporting 0 OPV doses
0.427 0.4 (0.04, 3.82) 1
Routine immunisation 80–100% of children under 2
with 3 DPT doses
baseline 0
<80% of children under 2
with 3 DPT doses
0.023 2.64 (1.57, 4.45) 1
Exposure to poliomyelitis
Bordering countries with wild
poliomyelitis in last 6 months
No baseline 0
Yes <0.001 4.77 (2.31, 9.88) 1
Migration and wild exposure Low baseline 0
Medium 0.060 1.77 (0.98, 3.2) 1
High <0.001 5.58 (2.93, 10.65) 1
Migration and wild poliomyelitis
exposure - expert opinion
Limited evidence of wild
poliomyelitis exposure
baseline 0
Evidence of wild poliomyelitis
exposure
not tested not tested 1
Susceptibility
Population displacement 0–10% of population
displaced
baseline 0
>10% of population
displaced
0.116 1.62 (0.89, 2.94) 1
Diarrhoea-associated mortality 0–199 deaths per 100,000 per
year in children <5 years
baseline 0
>200 deaths per 100,000 per
year in children <5 years
0.001 1.96 (1.1, 3.52) 1
Previous importations No wild poliomyelitis
importations in previous
4 years
baseline 0
Wild poliomyelitis
importations in previous
4 years
<0.001 2.75 (1.52, 4.97) 1
Humanitarian emergencies - expert opinion None reported baseline 0
Country of concern not tested not tested 1
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risk assessment covering these time periods. Within
these countries (except Madagascar), DTP3 immunisa-
tion was less than 80%, and in Guinea and South Sudan
DPT3 was less than 60% during this time but the
number of live-births were typically less than 500,000
per year. From one time-period to the next the
estimated risk for each country was similar owing to the
strong influence of birth numbers on cVDPV risk, and
other factors that only change slightly in value between
time periods.
Discussion
We have provided a comprehensive country-level analysis
of wild and cVDPV outbreak risk for 92 countries, based
on factors that describe population immunity, historical
propensity, exposure and susceptibility to poliomyelitis
Fig. 3 Location (a) and timing (b) of vaccine-derived poliomyelitis outbreaks within the AFRO, EMRO, SEARO and selected EURO countries,
2003–2016. The publication of this map does not imply the expression of any opinion whatsoever on the part of WHO concerning the
legal status of any territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries
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within a country. The modelling provides a framework for
assessing wild and cVDPV risk, which allows a robust com-
parison between countries and time-periods. The risk for
wild poliomyelitis has reduced since 2014, particularly in
the African continent, where countries classified as High
and Medium High have reduced from 31.7% in July–De-
cember 2014 to 9.0% in July–December 2016. The risk of
VDPVs has remained fairly constant, as shown by the low
but consistent number of cVDPV emergent events in time
and consistent geographical pattern of at-risk countries.
Wild poliomyelitis risk is associated with low popula-
tion immunity, increased population movements from
countries with wild poliomyelitis and factors that relate
to susceptibility. Country-level estimates of routine im-
munisation had the strongest association with wild type
outbreaks when compared to other approximate measures
of population immunity, where the variance in routine im-
munisation was approximately double the variance of the
percentage under-immunised via AFP data. Mass immun-
isation campaigns are designed to raise the percentage of
children who have received three or more OPV doses but
their impact on preventing outbreaks may be limited by
other factors, such as suboptimal SIA coverage, and access
to healthcare [28]. The association of diarrhoea-associated
mortality with an increased risk of wild poliomyelitis out-
breaks is likely to indicate reduced efficacy of the OPV
Table 3 Explanatory variables used in the risk score to assess vaccine-derived poliomyelitis outbreak risk, based on a regression
analysis of data from 2003 to 2016
Variable Factor p-value Risk estimate Risk score
Population Immunity
Routine 95+ baseline 0
immunisation 85–95 <0.001 1.51 (1.23, 1.85) 1
75–85 2.27 (1.85, 2.78) 1
65–75 3.42 (2.79, 4.19) 2
<65 5.15 (4.2, 6.31) 2
Under-immunised 0–20% of non-polio AFP reporting 0–2 OPV doses baseline 0
>20% of non-polio AFP reporting 0–2 OPV doses 0.18 1.48 (0.84, 2.61) 1
Zero dose 0–20% of non-polio AFP reporting 0 OPV doses baseline 0
>20% of non-polio AFP reporting 0 OPV doses 0.427 0.40 (0.04, 3.82) 1
Susceptibility
cVDPV outbreaks in last 0–4 years No baseline 0
Yes 0.005 3.41 (1.44, 8.07) 1
Population displacement 0–10% of population displaced baseline 0
>10% of population displaced 0.005 3.25 (1.43, 7.38) 1
Livebirths per year <500,000 baseline 0
<1,000,000 0.004 6.94 (1.86, 25.93) 2
+1 mill <0.001 29.32 (8.3, 103.48) 4
Table 4 Risk scores used to determine classification of countries according to wild and cVDPV risk and associated sensitivity,
specificity and historical probability of an outbreak
Classification Low Medium Medium high High
Wild-type assessment
Score from risk factors 0–2 3 4–5 6–8
% of observations associated with an outbreak (95% CI) 0.8 (0.4, 1.3) 5.6 (3.1, 8.2) 18.5 (14.3, 23.9) 35.2 (24.2, 46.4)
Sensitivity 100.0% 89.9% 69.7% 24.2%
Specificity 0.0% 67.9% 86.5% 97.5%
cVDPV-type assessment
Score from risk factors 0–3 4–5 6–7 8–9
% of observations associated with an outbreak (95% CI) 0.3 (0.1, 0.6) 2.5 (1.2, 4.1) 12.5 (4.1, 22.2) 34.3 (18.2, 51.6)
Sensitivity 100.0% 88.2% 67.6% 38.2%
Specificity 0.0% 73.1% 93.4% 99.0%
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that may be attributed to wider issues associated with
interference from other enteroviruses (which may result in
diarrhoea) and a high incidence of intestinal patho-
gens and associated environmental enteropathy [29, 31].
Additionally, the association with diarrhoeal disease may
indicate an increased transmission potential owing to cli-
matic factors, poor hygiene and lack of healthcare access
[30–32]. Population displacement may result in increased
exposure to poliovirus but also provide an indication of a
dysfunctional health system. For example estimates of dis-
placed persons of Syrian origin rose from <1% to >13% in
2012 [21] alongside a reduction of DPT3 estimates to
<50%, and a wild outbreak was reported in July 2013 [14].
Migration from countries with poliomyelitis cases is a
clear driver for wild poliomyelitis outbreaks and can be
regarded as a good predictor of risk. Data for inter-
national migration was available for only 2001 and reli-
able time-varying estimates are required [20]. Migration
routes are likely to change annually and there are no
consistent data sources that capture these changes, con-
sequently we opted to use expert opinion and time-
varying data on population displacement within the risk
assessment. Since 2013 a majority of poliomyelitis cases
on the African continent were part of the West Africa-
B1 lineage [33], which suggests that migration from
Nigeria had a large impact on poliomyelitis cases in the
African continent. Since this time Nigeria has substan-
tially limited transmission of wild poliovirus through
heightened surveillance, improvements in population
immunity, and a surge in technical capacity within the
country [34]. The recent cases in Borno State suggest
gaps in surveillance for acute flaccid paralysis and im-
munisation against poliomyelitis within a region heavily
affected by the Boko Haram insurgency [35]. Outbreaks
in the African continent within the last 2 years are likely
to have been contained and the last reported case of
poliomyelitis outside of Nigeria was in Somalia in Au-
gust 2014. Consequently, exposure to wild poliomyelitis
has substantially reduced across the African continent,
but as indicated via the risk assessment many countries
within Africa remain susceptible to outbreaks owing to
gaps in population immunity and susceptibility indica-
tors. While transmission of poliovirus continues, im-
provements in population immunity and surveillance for
cases remain vital. The South Asian (SOAS) lineage
of poliovirus, primarily found in Pakistan and
Afghanistan, was associated with outbreaks of poliomyel-
itis in Syria, Iraq [36] and China (not analysed here).
There are fewer examples of cross-border transmission of
the SOAS lineage, despite there being more recorded
migration from Pakistan and Afghanistan to other
countries when compared to Nigeria [20]. In countries
directly bordering Pakistan and Afghanistan (Iran, China,
Turkmenistan, Tajikistan, India) risk mitigation consists of
routine immunisation schedules including up to five OPV
doses and SIAs to prevent local transmission, resulting in
at least 90% of children under 2 reporting >3 OPV doses
[37]. It is therefore likely that these mitigation steps have
prevented outbreaks of poliomyelitis within these
countries.
The risk score has been used to inform the planning
of SIAs within the AFRO, SEARO, EMRO and EURO
regions. The multi-agency risk classifications are submit-
ted to the Eradication and Outbreak Management
Group of the GPEI, whose remit is to direct activities
that will support poliovirus detection and interruption
[38]. The allocation of SIAs is made according to the
perceived risk of wild and cVDPV outbreaks, available
vaccines, resources and finances [3]. Other steps to miti-
gate outbreaks include improving routine immunisation
coverage, adapting the routine immunisation schedule to
include more than three doses of OPV, inclusion of
immunisation teams at transit points in key locations
[19], and increased surveillance for cases of AFP [3]. All
of these activities require considerable resources and it
has been increasingly important to ensure that the lim-
ited resources available for polio eradication are placed
where they can be most effective. The risk assessment
will continue to be carried out until wild poliomyelitis
has been eliminated, but the methods may require some
adaptation, for example by including environmental
wastewater data, serological surveys and surveillance in-
dicators as they become available. The risk assessment
has been used by the GPEI to guide prioritisation of
countries in the African region for support to improve
case detection, SIA quality and outbreak preparedness in
2015 and again in 2016.
cVDPV risk has factors in common with wild outbreaks
such as population immunity, population displacement
and a previous history of reporting cVDPV outbreaks. The
origins of cVDPV outbreaks differ and this changes the as-
sociated risk factors and geographical distribution of risk.
Countries where over 1 million children are born each
year require suitable health systems to immunise these
children against poliomyelitis and other diseases, and in
these settings it is especially important to ensure at least
80% of children are immunised. In 2010, DRC, Ethiopia,
Nigeria, Pakistan, India and Indonesia were reported to
have more than a million births and routine immunisation
below 80%, indicating large numbers of children who may
be at-risk of cVDPVs. It is likely that the risk of cVDPV
emergence can be reduced with improved routine immun-
isation and SIAs [9], but campaigns with good coverage
will be critical to halt transmission. As of April 2016, the
inactivated polio vaccine and/or monovalent serotype 2
OPV will only be used in response to circulating virus of
that serotype. The model could predict risk in populous
countries with low routine immunisation, such as DRC
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and Pakistan, but had a poor ability to identify ahead of
time the risk associated with outbreaks in smaller coun-
tries such as Guinea, Madagascar, South Sudan and
Ukraine. Low sensitivity of the risk score may be improved
by including additional information that is not currently
routinely available. Expert opinion of the resilience of spe-
cific countries to cVDPVs (for example by quickly initiat-
ing an outbreak response), information from surveillance
reviews, reports on healthcare access within the country,
and sub-national estimates of routine immunisation to
account for heterogeneity in coverage [9], may provide
additional indicators of cVDPV risk. For example, con-
cerns about a reduction in routine immunisation services
during the Ebola outbreak in West Africa were reported
in early 2015 [39], and DPT3 coverage in Ukraine had
been below 80% since 2008 [40, 41]. A systematic way to
incorporate these changes in risk is required to improve
the accuracy of the risk assessment.
The inherent risk of cVDPVs associated with OPV use
means that the gradual withdrawal of the OPV is essen-
tial, and this process started in April 2016 by removing
the Sabin 2 strain from routine and SIAs and inclusion
of the inactivated polio vaccine in routine immunisation
[10]. This step will strongly influence the temporal and
geographical distribution of VDPV risk as it removes
direct exposure to Sabin 2 poliovirus. Long-term, circu-
lation of VDPV2 will reduce as emergence of VDPV
progenitors decline. Surveillance for cases of AFP and
poliovirus in wastewater samples will continue to be im-
portant in countries free from wild poliomyelitis as de-
tection and response of cVDPVs and its progenitors is
essential to prevent disease. Further research is required
to understand how the distribution and incidence of
cVDPVs of each serotype will change in the absence of
serotype 2, and the analysis presented here will be up-
dated to inform the surveillance and response activities
associated with cVDPVs.
The use of a risk score based on a regression model is
advantageous when compared to using the regression
model alone. The risks for additional countries and time
periods can be rapidly calculated and the reasons for
why specific countries have been allocated a score are
transparent, which can be advantageous when engaging
with stakeholders with limited statistical modelling ex-
perience. There was a small reduction in the H-measure
from using a risk score instead of the regression model,
but we considered this a minimal reduction. Measures
of the variation in uncertainty for each assessment are
not available when using the risk score, whereas the
prediction from the regression analysis includes esti-
mates of uncertainty. For the purposes described here,
statistical uncertainty of risk is not formerly considered
when used to prioritise SIAs, and so the risk classifica-
tion approach is the preferred option.
Conclusions
Use of the scoring system is a transparent and rapid
approach to assess country risk of wild and vaccine-
derived poliomyelitis outbreaks. Within the time
period of the analyses there has been a steep reduc-
tion in the number of wild poliomyelitis outbreaks
and the reduction in countries classified as High and
Medium High risk has reflected this. Vaccine-derived
poliomyelitis outbreak risk has remained relatively
constant over time but the location of at-risk
countries has changed geographically. These findings
highlight that many countries remain susceptible to
poliomyelitis outbreaks and maintenance or improve-
ment in routine immunisation is vital.
Looking forward, this analysis provides an assess-
ment of risk for guidance of immunisation activities
against poliomyelitis based on the available evidence
and historical patterns of wild and cVDPV outbreaks.
The analysis may also assist with prioritization of
poliomyelitis surveillance and social mobilization
activities by highlighting countries where further in-
vestment is required. As the incidence of poliomyelitis
reduces and transmission is stopped within endemic
countries, SIAs with the OPV will likely reduce in
line with the declining risk [42]. However, it will be
important to remain responsive to the risk of outbreaks
this framework can be used to inform immunisation
activities and ensure that they are proportionate to
the perceived risks.
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